What is the MOA for Entyvio and how does it work?

Entyvio (vedolizumab) works by targeting α4β7 integrin, a protein that plays a role in gut inflammation. It blocks the interaction between α4β7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1), preventing immune cells (T-lymphocytes) from migrating into the gastrointestinal tract.

This mechanism helps reduce inflammation associated with ulcerative colitis (UC) and Crohn’s disease, leading to symptom relief.

Is Entyvio a biologic?

Yes, Entyvio (vedolizumab) is a biologic medication. It is a monoclonal antibody that belongs to the drug class called integrin receptor antagonists, which specifically target immune system activity in the gut.

What is Entyvio used for?

Entyvio is an injection that is FDA approved to treat moderate-to-severe ulcerative colitis and Crohn’s disease in adults. It was initially approved in May 2014 to treat these conditions as an intravenous infusion, and later approved as a subcutaneous (under the skin) injection.

Who manufactures Entyvio?

Entyvio is manufactured by Takeda Pharmaceuticals, based in Cambridge, MA. You can contact them at 1-877-825-3327.

This is not all the information you need to know about Entyvio (vedolizumab) for safe and effective use and does not take the place of your doctor’s directions. Review the full product information and discuss this information and any questions you have with your doctor or other health care provider.